Join Growin Stock Community!

Hologic, inc.HOLX.US Overview

US StockHealthcare
(No presentation for HOLX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HOLX AI Insights

HOLX Overall Performance

HOLX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HOLX Recent Performance

-0.13%

Hologic, inc.

0.05%

Avg of Sector

-0.31%

S&P500

HOLX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HOLX Key Information

HOLX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HOLX Profile

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Price of HOLX

HOLX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HOLX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.44
PE Ratio (TTM)
31.27
Forward PE
15.91
PS Ratio (TTM)
4.08
PB Ratio
3.20
Price-to-FCF
17.84
METRIC
VALUE
vs. INDUSTRY
Gross Margin
51.47%
Net Margin
13.18%
Revenue Growth (YoY)
2.17%
Profit Growth (YoY)
-5.22%
3-Year Revenue Growth
-0.83%
3-Year Profit Growth
-1.73%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.44
PE Ratio (TTM)
31.27
Forward PE
15.91
PS Ratio (TTM)
4.08
PB Ratio
3.20
Price-to-FCF
17.84
Gross Margin
51.47%
Net Margin
13.18%
Revenue Growth (YoY)
2.17%
Profit Growth (YoY)
-5.22%
3-Year Revenue Growth
-0.83%
3-Year Profit Growth
-1.73%

  • When is HOLX's latest earnings report released?

    The most recent financial report for Hologic, inc. (HOLX) covers the period of 2026Q1 and was published on 2025/12/27. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HOLX's short-term business performance and financial health. For the latest updates on HOLX's earnings releases, visit this page regularly.

  • Where does HOLX fall in the P/E River chart?

    According to historical valuation range analysis, Hologic, inc. (HOLX)'s current price-to-earnings (P/E) ratio is 30.78, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of HOLX?

    According to the latest financial report, Hologic, inc. (HOLX) reported an Operating Profit of 237M with an Operating Margin of 22.62% this period, representing a growth of 3.13% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is HOLX's revenue growth?

    In the latest financial report, Hologic, inc. (HOLX) announced revenue of 1.05B, with a Year-Over-Year growth rate of 2.54%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does HOLX have?

    As of the end of the reporting period, Hologic, inc. (HOLX) had total debt of 2.52B, with a debt ratio of 0.27. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does HOLX have?

    At the end of the period, Hologic, inc. (HOLX) held Total Cash and Cash Equivalents of 2.17B, accounting for 0.24 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does HOLX go with three margins increasing?

    In the latest report, Hologic, inc. (HOLX) achieved the “three margins increasing” benchmark, with a gross margin of 56%%, operating margin of 22.62%%, and net margin of 17.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HOLX's profit trajectory and future growth potential.

  • Is HOLX's EPS continuing to grow?

    According to the past four quarterly reports, Hologic, inc. (HOLX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.8. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of HOLX?

    Hologic, inc. (HOLX)'s Free Cash Flow (FCF) for the period is 194.8M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 23.53% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of HOLX?

    The latest valuation data shows Hologic, inc. (HOLX) has a Price-To-Earnings (PE) ratio of 30.78 and a Price/Earnings-To-Growth (PEG) ratio of -4.9. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.